ROIV Valuation

Roivant Sciences Ltd

Add to Watchlist

Advanced Chart

11.840

+0.2(1.718%)1D

Overview
Forecast
Valuation
Earnings

ROIV Relative Valuation

ROIV's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ROIV is overvalued; if below, it's undervalued.

Historical Valuation

Roivant Sciences Ltd (ROIV) is now in the Overvalued zone, suggesting that its current forward PS ratio of 269.36 is considered Overvalued compared with the five-year average of -7.12. The fair price of Roivant Sciences Ltd (ROIV) is between 0.78 to 5.21 according to relative valuation methord. Compared to the current price of 11.84 USD , Roivant Sciences Ltd is Overvalued By 127.18%.

Relative Value

Fair Zone

0.78-5.21

Current Price：11.84

127.18%

Overvalued

-8.35

Trailing

Forward

-3.49

EV/EBITDA

Roivant Sciences Ltd. (ROIV) has a current EV/EBITDA of -3.49. The 5-year average EV/EBITDA is -3.06. The thresholds are as follows: Strongly Undervalued below -7.90, Undervalued between -7.90 and -5.48, Fairly Valued between -0.63 and -5.48, Overvalued between -0.63 and 1.79, and Strongly Overvalued above 1.79. The current Forward EV/EBITDA of -3.49 falls within the Historic Trend Line -Fairly Valued range.

-3.79

EV/EBIT

Roivant Sciences Ltd. (ROIV) has a current EV/EBIT of -3.79. The 5-year average EV/EBIT is -2.56. The thresholds are as follows: Strongly Undervalued below -8.12, Undervalued between -8.12 and -5.34, Fairly Valued between 0.22 and -5.34, Overvalued between 0.22 and 3.00, and Strongly Overvalued above 3.00. The current Forward EV/EBIT of -3.79 falls within the Historic Trend Line -Fairly Valued range.

269.36

Roivant Sciences Ltd. (ROIV) has a current PS of 269.36. The 5-year average PS is 68.23. The thresholds are as follows: Strongly Undervalued below -57.76, Undervalued between -57.76 and 5.24, Fairly Valued between 131.22 and 5.24, Overvalued between 131.22 and 194.22, and Strongly Overvalued above 194.22. The current Forward PS of 269.36 falls within the Strongly Overvalued range.

-10.77

P/OCF

Roivant Sciences Ltd. (ROIV) has a current P/OCF of -10.77. The 5-year average P/OCF is -9.30. The thresholds are as follows: Strongly Undervalued below -31.64, Undervalued between -31.64 and -20.47, Fairly Valued between 1.87 and -20.47, Overvalued between 1.87 and 13.04, and Strongly Overvalued above 13.04. The current Forward P/OCF of -10.77 falls within the Historic Trend Line -Fairly Valued range.

-5.74

P/FCF

Roivant Sciences Ltd. (ROIV) has a current P/FCF of -5.74. The 5-year average P/FCF is -7.40. The thresholds are as follows: Strongly Undervalued below -18.39, Undervalued between -18.39 and -12.89, Fairly Valued between -1.90 and -12.89, Overvalued between -1.90 and 3.59, and Strongly Overvalued above 3.59. The current Forward P/FCF of -5.74 falls within the Historic Trend Line -Fairly Valued range.

Roivant Sciences Ltd (ROIV) has a current Price-to-Book (P/B) ratio of 1.83. Compared to its 3-year average P/B ratio of 3.71 , the current P/B ratio is approximately -50.73% higher. Relative to its 5-year average P/B ratio of 3.00, the current P/B ratio is about -39.00% higher. Roivant Sciences Ltd (ROIV) has a Forward Free Cash Flow (FCF) yield of approximately -10.55%. Compared to its 3-year average FCF yield of -12.19%, the current FCF yield is approximately -13.47% lower. Relative to its 5-year average FCF yield of -30.90% , the current FCF yield is about -65.87% lower.

1.83

P/B

Median3y

3.71

Median5y

3.00

-10.55

FCF Yield

Median3y

-12.19

Median5y

-30.90

Competitors Valuation Multiple

The average P/S ratio for ROIV's competitors is 59.07, providing a benchmark for relative valuation. Roivant Sciences Ltd Corp (ROIV) exhibits a P/S ratio of 269.36, which is 356.04% above the industry average. Given its robust revenue growth of -72.84%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Jazz Pharmaceuticals PLC

Corcept Therapeutics Inc

Madrigal Pharmaceuticals Inc

Loss

1353.76%

9.47B

Performance Decomposition

Market capitalization of ROIV decreased by 3.19% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -395.53 to -12.62K.

The secondary factor is the Revenue Growth, contributed -72.84%to the performance.

Overall, the performance of ROIV in the past 1 year is driven by Margin Expansion. Which is more sustainable.

-72.84%

7.99M → 2.17M

Revenue Growth

3091.32%

-395.53 → -12.62K

Margin Expansion

-3021.67%

0.37 → -10.67

P/E Change

-3.19%